Regressions and cures of melanoma xenografts following treatment with monoclonal antibody beta-lactamase conjugates in combination with anticancer prodrugs.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Cancer Research

• Publication date

  1995-08-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 7627964
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antitumor properties of vindesine-monoclonal antibody conjugates

  2004cited by this paper
• Cancer principles and practice of oncology

  1997cited by this paper
• Synthesis and beta-lactamase-mediated activation of a cephalosporin-taxol prodrug.

  1995cited by this paper
• Cephalosporin derivatives of doxorubicin as prodrugs for activation by monoclonal antibody-beta-lactamase conjugates.

  1995cited by this paper
• Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug.

  1995cited by this paper
• In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates.

  1995cited by this paper
• Synthesis and β-lactamase-mediated activation of a cephalosporin-taxol prodrug

  1995cited by this paper
• Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185.

  1994cited by this paper
• Synthesis and characterization of monoclonal antibody-beta-lactamase conjugates.

  1994cited by this paper
• BR96-Doxorubicin Conjugate (BMS-182248) Versus Doxorubicin: A Comparative Toxicity Assessment in Rats

  1994cited by this paper
• Antimicrobial activity of a new antipseudomonal dual-action drug, Ro 25-0534.

  1994cited by this paper
• Targeting enzymes for cancer therapy: old enzymes in new roles.

  1994cited by this paper
• beta-Lactamase hydrolysis of cephalosporin 3'-quinolone esters, carbamates, and tertiary amines

  1994cited by this paper
• Tumor-selective prodrug activation by fusion protein-mediated catalysis.

  1994cited by this paper
• Antitumor Activities of a Cephalosporin Prodrug in Combination with Monoclonal Antibody‐β‐lactamase Conjugates.

  1994cited by this paper
• Antibody-Directed Enzyme Prodrug Therapy

  1994cited by this paper
• Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine.

  1994cited by this paper
• Antitumor activities of a cephalosporin prodrug in combination with monoclonal antibody-beta-lactamase conjugates.

  1993cited by this paper
• Generation of cytotoxic agents by targeted enzymes.

  1993cited by this paper
• Cutaneous melanoma.

  1993cited by this paper
• Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G amidase conjugate.

  1993cited by this paper
• Site-specific prodrug activation by antibody-beta-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models.

  1993influential reference
• Synthesis and release of doxorubicin from a cephalosporin based prodrug by a β-lactamase-immunoconjugate

  1993cited by this paper
• Design and Synthesis of a Cephalosporin-Carboplatinum Prodrug Activatable by a β-Lactamase.

  1993cited by this paper
• N-(4'-hydroxyphenylacetyl)palytoxin: a palytoxin prodrug that can be activated by a monoclonal antibody-penicillin G amidase conjugate.

  1992cited by this paper
• An unmodified anticarcinoma antibody, BR96, localizes to and inhibits the outgrowth of human tumors in nude mice.

  1992cited by this paper
• Monoclonal antibody-beta-lactamase conjugates for the activation of a cephalosporin mustard prodrug.

  1992cited by this paper
• Cephalosporin Nitrogen Mustard Carbamate prodrugs for “ADEPT”.

  1991cited by this paper
• Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates.

  1991cited by this paper
• Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice.

  1990cited by this paper
• Pilot trial of murine monoclonal antibodies in patients with advanced melanoma.

  1985cited by this paper
• Human melanoma cells can be killed in vitro by an immunotoxin specific for melanoma‐associated antigen p97

  1982cited by this paper
• 1 – Determination of Equilibrium Binding Parameters of Monoclonal Antibodies Specific for Cell Surface Antigens

  1981cited by this paper
• Analysis of normal neoplastic human tissues for the tumor‐associated protein p97

  1981cited by this paper
• Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies.

  1981cited by this paper
• Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

  1978cited by this paper

• A glimpse into the developments, potential leads and future perspectives of anticancer cobalt complexes.

  2025cites this paper
• Metal‐Catalyzed Cross‐Coupling for the Synthesis of β‐Lactam Drugs and Related Chemical Probes

  2025cites this paper
• Micelles with ultralow critical micelle concentration as carriers for drug delivery

  2018cites this paper
• Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination

  2017cites this paper
• Metabolic Activation and Drug Targeting

  2016cites this paper
• Directed Enzyme Prodrug Therapies

  2011cites this paper
• Cancer cell-specific internalizing ligands from phage displayed beta-lactamase-peptide fusion libraries.

  2010cites this paper
• Phage-displayed combinatorial peptide libraries in fusion to beta-lactamase as reporter for an accelerated clone screening: Potential uses of selected enzyme-linked affinity reagents in downstream applications.

  2010cites this paper
• Synthetic DNA-Targeted Chemotherapeutic Agents And Related Tumor-Activated Prodrugs

  2010cites this paper
• Developing bifunctional β‐lactamase molecules with built‐in target‐recognizing module for prodrug therapy: identification of Enterobacter Cloacae P99 cephalosporinase loops suitable for randomization and phage‐display selection

  2009influential citation
• Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies.

  2009cites this paper
• Novel β-lactamase-random peptide fusion libraries for phage display selection of cancer cell-targeting agents suitable for enzyme prodrug therapy

  2009cites this paper
• Prodrug Strategies in Anticancer Chemotherapy

  2008cites this paper
• Novel antibodies as anticancer agents

  2007cites this paper
• Towards a ligand targeted enzyme prodrug therapy: Single round panning of a β‐lactamase scaffold library on human cancer cells

  2007cites this paper
• Sequence-Specific DNA Detection Utilizing Custom-Designed Zinc Finger Proteins

  2007cites this paper
• Analysis for a free boundary problem modeling tumor therapy

  2006cites this paper
• Antibody-directed enzyme prodrug therapy (ADEPT) for cancer

  2006cites this paper
• Selective delivery of therapeutic agents for the diagnosis and treatment of cancer

  2006cites this paper
• Prodrugs of anthracyclines in cancer chemotherapy.

  2006cites this paper
• Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines.

  2006cites this paper
• Systems biology and the mathematical modelling of antibody-directed enzyme prodrug therapy (ADEPT).

  2005cites this paper
• Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy.

  2004cites this paper
• Tumor-activated Prodrugs—A New Approach to Cancer Therapy

  2004cites this paper
• Enzyme-Catalyzed Activation of Anticancer Prodrugs

  2004influential citation
• Fluctuations and noise in cancer development

  2004cites this paper
• Antibody-directed enzyme prodrug therapy (ADEPT) for cancer

  2004cites this paper
• Intracellular accumulation and mechanism of action of doxorubicin in a spatio-temporal tumor model.

  2003cites this paper
• Cephalosporin prodrugs of paclitaxel for immunologically specific activation by L-49-sFv-beta-lactamase fusion protein.

  2003cites this paper
• Antibody Penetration into a Spherical Prevascular Tumor Nodule Embedded in Normal Tissue

  2002cites this paper
• Prodrug and antedrug: Two diametrical approaches in designing safer drugs

  2002cites this paper
• Vascular tumor growth and treatment: Consequences of polyclonality, competition and dynamic vascular support

  2002cites this paper
• Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.

  2001cites this paper
• Prodrug strategies in cancer therapy.

  2001cites this paper
• Synthesis and preliminary cytotoxicity study of a cephalosporin-CC-1065 analogue prodrug

  2001cites this paper
• Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug.

  2001cites this paper
• Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX‐GA3 in combination with a monoclonal antibody β‐glucuronidase conjugate

  2001cites this paper
• Potentiation of antitumor immunity by antibody‐directed enzyme prodrug therapy

  2001cites this paper
• A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy.

  2000influential citation
• Development and validation of a mathematical model to describe anti-cancer prodrug activation by antibody-Enzyme conjugates

  2000cites this paper
• Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy.

  2000cites this paper
• Self-immolative anthracycline prodrugs for suicide gene therapy.

  1999cites this paper
• Comparison of recombinant and synthetically formed monoclonal antibody-beta-lactamase conjugates for anticancer prodrug activation.

  1999cites this paper
• Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug.

  1999cites this paper
• Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs.

  1999cites this paper
• Theoretical analysis of conjugate localization in two-step cancer chemotherapy

  1999cites this paper
• Mathematical and experimental analysis of localization of anti-tumour antibody–enzyme conjugates

  1999cites this paper
• A strategy for the isolation of catalytic activities from repertoires of enzymes displayed on phage.

  1999cites this paper
• Immune and gene therapy for melanoma, and the immunobiology of melanoma

  1999cites this paper
• The Design and Synthesis of Prodrugs for Antibody-Directed Enzyme Prodrug Therapy (ADEPT)

  1999cites this paper
• Enzyme-Prodrug Strategies for Cancer Therapy

  1999cites this paper
• Development and activities of a new melphalan prodrug designed for tumor-selective activation.

  1998cites this paper
• Therapeutic effects of monoclonal antibody-beta-lactamase conjugates in combination with a nitrogen mustard anticancer prodrug in models of human renal cell carcinoma.

  1998cites this paper
• The antitumour activity of the prodrug N-L-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts.

  1998cites this paper
• Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means.

  1998cites this paper
• Affinity reagents against tumour-associated extracellular molecules and newforming vessels.

  1998cites this paper
• Effects of a Hybrid Recombinant Human Alpha Interferon (A/D) on in vitro Cytotoxicity and in vivo Localization of Monoclonal Antibody L6-Cytosine Deaminase Conjugate in a Colon Cancer Model

  1998cites this paper
• The development of monoclonal antibodies for the therapy of cancer.

  1998cites this paper
• Novel therapeutic strategies to selectively kill cancer cells.

  1998cites this paper
• Technique for Repeatable Hyperosmotic Blood-Brain Barrier Disruption in the Dog

  1997cites this paper
• Toward Antibody-directed Enzyme Prodrug Therapy with the T268G Mutant of Human Carboxypeptidase A1 and Novel in VivoStable Prodrugs of Methotrexate*

  1997cites this paper
• Antibody-directed enzyme prodrug therapy (ADEPT): a review.

  1997cites this paper
• Bioorganometallic Chemistry – Synthesis and Antitumor Activity of Cobalt Carbonyl Complexes

  1997cites this paper
• Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation.

  1997cites this paper
• Immunologically specific activation of a cephalosporin derivative of mitomycin C by monoclonal antibody beta-lactamase conjugates.

  1997cites this paper
• Molecular pharmacology of a series of nitrogen mustard-containing and AT- and GC recognising minor groove binding agents related to distamycin.

  1996cites this paper
• A summary of monoclonal antibody-enzyme/prodrug

  1996cites this paper
• Computer-aided prediction of prodrug activity using the pass system

  1996cites this paper
• Antibody-directed enzyme prodrug therapy (ADEPT).

  1996cites this paper
• AN-nitrosochloroethyl-cephalosporin carbamate prodrug for antibody-directed enzyme prodrug therapy (ADEPT)

  1996cites this paper
• Alkylating agent prodrugs for ADEPT

  1996cites this paper
• Antibody-directed enzyme prodrug therapy (ADEPT).

  1996cites this paper
• Antibody-directed enzyme prodrug therapy for cancer: its theoretical basis and application.

  1995cites this paper
• Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.

  1994cites this paper
• Synthetic DNA‐Targeted Chemotherapeutic Agents And Related Tumor‐Activated Prodrugs

  year unknowncites this paper